Abstract. The HSP90 molecular chaperone family is highly conserved and expressed in various organisms ranging from prokaryotes to eukaryotes. HSP90 proteins play essential housekeeping functions, such as controlling the activity, turnover and trafficking of various proteins, promoting cell survival through maintaining the structural and functional integrity of some client proteins which control cell survival, proliferation and apoptosis, and play an important role in the progression of malignant disease. HSP90 proteins are ATPdependent chaperones and the binding and hydrolysis of ATP are coupled to conformation changes of HSP90, which facilitate client protein folding and maturation. Many natural and synthetic molecular compounds have been proposed as promising cancer therapy via disrupting the formation of complex ATP-HSP90-client proteins. 
Introduction
The HSP90 molecular chaperone family is highly conserved and expressed in various organisms ranging from prokaryotes to eukaryotes and even under normal conditions HSP90 proteins account for 1-2% of all cellular proteins in most cells (1) . The expression of HSP90 is elevated up to 10-fold when exposed to physiologic stress including heat, heavy metals, hypoxia and low pH (2, 3) . HSP90 proteins play essential housekeeping functions, such as controlling the activity, turnover and trafficking of various proteins, promoting cell survival through maintaining the structural and functional integrity of some client proteins which control cell survival, proliferation and apoptosis (4, 5) . Many reports have indicated that HSP90 proteins play an important role in the progression of malignant disease and HSP90 expression is 2-to 10-fold higher in tumor cells than in normal cells (6) (7) (8) . HSP90 sustains cancer cells through interacting smoothly with client substrates which contain kinases, hormone receptors and transcription factors directly involved in evoking multi-step malignancies, and also with mutated oncogenic proteins necessary for transformed phenotype (9) . Therefore, HSP90 has been proposed as a promising target for therapy of various human cancers.
Structure and function
Researchers indicated that the HSP90 molecular chaperone family is present in the cytosol, nucleoplasm, endoplasmic reticulum (ER), mitochondria and chloroplasts (1, 10, 11) . Members of the human HSP90 chaperone family are listed in Table I . There are four kinds of isoforms, including HSP90· (90 kDa heat-shock protein), HSP90ß, Grp94 (94 kDa glucose-regulated protein) and TRAP1 (tumor necrosis factor receptor-associated protein 1) (1, (12) (13) (14) . HSP90· and HSP90ß are cytosolic proteins and share 76% homology due to gene duplication during evolution (1, 15) . Mainly Grp94 resides in the endoplasmic reticulum (ER), while TRAP1 is a mitochondrial paralogue and connected with Eubacterial HtpG (14, 16, 17) . In addition, a novel member of the HSP90 family called HSP90N was reported to be related with neoplastic transformation (18) . ONCOLOGY REPORTS 23: 1483 -1492 The crystal structures of HSP90 proteins from Escherichia coli, yeast and human have shown that the basic domain is conserved, although it become more complex with multifunction from procaryote to eukaryote (19) (20) (21) (22) (23) (24) . Hsp90 chaperones exist as obligate homodimers, with each identical subunit comprised of an N-terminal domain, a middle domain, a non-conserved charged middle linker region which connects the N-terminal domain with the middle domain, and a Cterminal domain (19) (20) (21) (22) (23) (24) . There are two ATP binding sites, one is on the N-terminus and the other is on the C-terminus (25) . The C-terminal domain contains a calmodulin binding site and dimerization site associating with its partner domain in the corresponding subunit to form dimer (1, 18, 26, 27) . A conserved pentapeptide sequence (MEEVD) lies in the extended C-terminal end of the eucaryotic protein, which serves as the primary binding site for tetratricopeptide repeat (TRP-a 34 amino acid sequence specifically binding to HSP90) domain containing co-chaperones (28) (29) (30) . The middle domin of HSP90 exhibits a high affinity for co-chaperones and client proteins and seems to discriminate between different substrate types and to adjust the molecular chaperone for the proper substrate activation (31) (32) (33) (34) (35) .
HSP90 and its inhibitors (Review)
The crystallization and three-dimensional structure analysis of the N-terminal domain is a milestone in the scientific exploration of the HSP90 molecular chaperone family (21, 23, 36) . Subsequently, the crystal structure of the HSP90-geldanamycin binding domain was reported to be a pocket which is also a likely binding site for the polypeptide substrate. So geldanamycin inhibits the HSP-catalyzed conformational reaction of these substrates via binding to the pocket (23) . Another researcher group reported a different complex of crystal structures between the N-terminal domain of the yeast HSP90 chaperone and ADP/ATP comprised of a specific adenine nucleotide binding site homologous to the ATPbinding site of DNA, suggesting that geldanamycin works by blocking the binding of nucleotides to Hsp90 (21) . A similar model was proposed in which the HSP90-geldanamycin binding domain is an ATP/ADP switch domain that regulates HSP90 conformation and the GA binding to HSP90 locks the chaperone into its ADP-dependent configuration (37) . In subsequent years, it was established that Hsp90 is an ATPdependent chaperone and the binding and hydrolysis of ATP are coupled to conformation changes of HSP90, which facilitate client protein folding and maturation and are disrupted by geldanamycin (38) (39) (40) (41) (42) .
In recent years, more complex and detailed mechanisms of the ATP-driven chaperone cycle of HSP90 have been intensively explored. A crystal structure of complex with full length yeast HSP90 and an ATP analogue directly confirms that the N-terminal dimerization is necessary for the ATP hydrolysis which accompanies conformation change of client proteins (22) . They further indicated that upon the ATPbound state, the N-terminus and lid segment (residues of the N domain and the catalytic loop of the middle segment together act as conformational switches to position the two halves of the catalytic apparatus for ATP hydrolysis (22) . At the same time Buchner et al (2) proposed a model to explain how ATP hydrolysis is regulated and linked to conformational changes which is consistent with the crystal structure of full length yeast HSP90 and ATP. i) The stable structure of the first 24 amino acids and the lid region within the Nterminal domain preclude N-terminal dimerization; ii) upon binding of the ATP, this stable structure is opened, the dimerization site becomes accessible, and the N-terminal strands are exchanged with corresponding monomeric subunit to form the ATPase-active state; iii) after N-terminal dimerization, the positioning of the ATP-lid in its new orientation is required for the ATP-hydrolyzing reaction in this domain; iv) the association of the N-terminal domain with the middle domain of HSP90 is necessary for efficient hydrolysis (43) .
Shiau et al further proposed a unified structurally validated mechanism model linking HSP90 ATPase activity and client protein binding and release. They indicated that a distinct set of lid segment conformation is responsible for coupling the nucleotide binding and hydrolysis to a cycle of domain rearrangements, which in turn regulate client-protein binding and release (19) . i) Without the binding of ATP, HSP90 presents multiple hydrophobic elements into the central cleft, containing the hydrophobic patch formed by one face of the lid segment which in an inactive state as well as helix H1. The most hydrophobic surface area of the central cleft is supposed to be the most optimal for client-protein binding. ii) The ATP binding drives lid rearrangement and reorientation of the N-terminal domain and the middle domain, to which client proteins could be bound in the central cavity in this ATP-containing intermediate state of HSP90. iii) After rearrangement, the lid stabilizes N-terminal domain dimerization via interaction with N-terminal domain residues of the partner protomer and this ATP-mediated closing of the interprotomer space could very well drive client-protein remodeling. iv) With the dimerization of the N-terminal domain of subunits, the ATP hydrolysis occurs and the lid changes conformation accordingly, this new lid conformation allows the interdigitation of the lid, the src loop, and the CTD Table I . Human HSP90 chaperone family. 
H21, mutually masking their otherwise exposed hydrophobic core, and finally assures complete release of client proteins from HSP90 (19).
HSP90 inhibitors
Considering the extremely important function of HSP90 in organisms, especially in the occurrence and development of various tumors, targeting HSP90 is considered to have bright future. Through knowledge of the ATP-driven chaperone cycle of Hsp90, it might be possible to identify and design small molecule compounds which selectively affect the different stages of the cycle, thus providing more selective and effective therapeutics. In fact the exploring function of HSP90 is accompanied by the development of small inhibitors targeting HSP90, so far many kinds of HSP90 inhibitors have been identified which are listed in Table II and many of them have already exhibited good antitumor effects and have entered into clinical trials. The following will introduce the various kinds of natural and synthetic HSP90 inhibitors.
Geldanamycin. Geldanamycin (GA) is a kind of benzoquinone ansamycin antibiotic. As early as 1994, researchers proposed the ability of GA to revert the transformed phenotype of v-src-transformed cells via binding to HSP90 and disrupting its chaperone function (44) . Subsequently, the identification of the ADP/ATP binding site in the N-terminal of HSP90 has driven the understanding of the inhibition mechanism of GA for cancer cells (21, 23, 36) . GA competitively binds to the N-terminal ATP binding site of HSP90, which prevents ATP binding and disrupts the ATP-dependent conformational cycling reactions of a wide range of client proteins involved in signal transduction, cell cycle regulation and hormone responsiveness (21, 23, 38) . Although GA exhibits potent antitumor effects, it also showed high hepatotoxicity and poor solubility in preclinical studies in animals, which has driven the development of geldanamycin analogues (45) . One possible reason of the toxicity is the C-17 methoxy group, which is reactive toward nucleophiles usually present in biological molecules. Replacement of the methoxy moiety at C-17 of GA with alkylamino groups are less reactive to nucleophiles and possess excellent biological activity and reduced hepatotoxicity (46) .
The tolerance at the 17-position for diverse substituents does not affect the formation of HSP90 and geldanamycin or its derivatives (47) . So 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), the 17-position derivate of GA, was developed and has shown to have lower in vivo toxicity than GA with even less HSP90 affinity than GA (48). 17-AAG has promising anticancer effects in vitro and in vivo and has completed phase I clinical trials and is in phase II trials for several malignancies including metastatic melanoma, breast and ovarian cancer (49) (50) (51) (52) . However, poor water solubility makes formulation a barrier for its clinical application (53) (54) (55) . Additional organic excipients such as dimethylsulfoxide (DMSO), polyoxylcastoroil (Cremophor) and egg phospholipida have been used as vehicles (53, 56) . However, these excipients may confuse the true maximum tolerated dose of 17-AAG and identificiation of the optional dosing regimen in patients due to their own toxicities. With low doses of 17-AAG in DMSO, researchers did not get objective antitumor responses in several phase II trials including melanoma, hormonerefractory prostate cancer and renal cell carcinoma (52, 57) . In addition, several characteristics of the chemical structure of 17-AAG have restricted fulfilling the maximal potential of its target in tumor cells (58) . A benzoquinone moiety of the molecule has been related to the observed elevation of liver enzymes and liver toxicity in clinical trials. On the other hand, the expression of (P-gp) or loss or mutation of the NQO1 gene, which is necessary for the bio-reduction of 17-AAG, to the more potent hydroquinone have been proposed as mechanisms of de novo or acquired resistance to 17-AAG (58) .
The difference between the 17-AAG and 17-DMAG is in the side chain at position 17 of the ansa ring (59). 17-Dimethyl- Table II. HSP90 inhibitors. 
aminoethylamino-17-demethoxygeldanamycin hydrochloride (17-DMAG, NSC 707545) is a more potent, more water soluble derivative of 17-AAG and has potent inhibitory effects on cell proliferation in cultured tumor cell lines and in vivo xenografts, and is currently in phase I clinical trials (60, 61) . 17-DMAG can be administered orally, which possibly makes it a more feasible long-term therapeutic agent for treating disease (62) . 17-DMAG is stable for at least 2 months at room temperature, less bound to plasma proteins compared to 17-AAG, and undergoes limited metabolism (53, (62) (63) (64) . Also, the limited metabolism of 17-DMAG compared to 17-AAG in prelinical models may reduce drug clearance and interindividual pharmacokinetic variability in humans (62, 65) .
IPI-504 is a highly soluble hydroquinone hydrochloride and novel analogue of 17-allylamino-17-demethoxygeldanamycin, which has >200 mg/ml solubility, thereby facilitating formulation for parenteral administration (55, 66) . The free base of IPI-504 is a potent inhibitor of Hsp90, which exists in a dynamic intracellular equilibrium with 17-AAG (55, 66) . The half-life of IPI-504 is ~6 h in vivo, though significant accumulation occurs within tumor cells (66) . Phase I trials of IPI-504 in patients with multiple myeloma (MM) and gastrointestinal stromal tumor (GIST) exhibited that the agent was well tolerated at doses up to 300 mg/m 2 (67) . Researchers have also synthesized other series of GA or 17-AAG by modification at the various positions. The C-11 modified analogues of GA and 17-AAG were identified with slightly improved cytotoxicity over 17-AAG against several cancer cell lines. The in vitro efficacy and pharmacological profiles of these compounds need further investigation to determine whether these compounds hold any advantages over 17-AAG (68) .
Radicicol. Radicicol is a 14-membered macrolide originally isolated from Monosporium bonorden as an anti-fungal antibioticin in 1953 (69) . Researchers found that radicicol has the ability to reverse the transformed phenotype in v-src, ras, mos, raf, fos and SV40-transformed cell lines to the normal one and inhibits the expression of mitogen-inducible cyclooxygenase in macrophages (70) (71) (72) (73) . Radicicol causes cell cycle arrest in the G1 and G2 phase and inhibits angiogenesis in vivo (74) . Crystal structure analysis has demonstrated that radicicol acts as a nucleotide mimic, inserting itself into the ATP/ADP-binding pocket of HSP90 (75) . Other research groups also indicated that radicicol could bind to the Nterminal GA binding site of HSP90 protein with 50-fold greater affinity and thus destabilize its client proteins (76) (77) (78) . Radicicol was found to show potent in vitro anti-proliferative activity against a wide variety of human tumor cell lines, but was inactive when tested against in vivo antitumor models (79) .
Radicicol lacks in vivo antitumor activity because the inhibitory effect of radicicol against tyrosine kinases is abolished by reducing agents such as DTT, thus many novel series of derivatives of radicicol have been generated with better stability and biologic activity (71, 80, 81) .
Oxime derivatives were developed and shown to be stable in the presence of thiol (81) such as KF25706, KF29518 and KF58333 were designed and synthesized and were found to show more potent anti-proliferative activities than radicicol and significant in vivo antitumor activities in several human tumor xenograft models (79, 82) . Researchers reported that KF25706 destabilized HSP90-associated molecules via binding to the HSP90 as radicicol in vitro and exhibited potent antitumor effects in vivo (79) . KF58333, also a novel derivative of radicicol, was reported to bind to the Hsp90 chaperone machinery, deplete p210Bcr-Abl and Raf-1 proteins followed by induction of erythroid differentiation and G1 phase accumulation, and to induce apoptosis in human CML cells (80) .
A new family of resocyclic macrolides was isolated from the fermentation of Pochonia chlamydosporia and named pochonin A-F (83). Pochonin A is closely related to radicicol and was shown to be a 90-nm inhibitor of HSP90 (83) . Pochonin C is also closely related to radicicol and can convert into radicicol (84) .
Radamide. Based on the knowledge of co-crystal structures of the HSP90 N-terminal ATP-binding site with radicicol and GA, a chimeric inhibitor, radanamycin amide (radamide), was designed and synthesized via incorporating the key binding interactions provided by the resorcinol ring of radicicol and the quinone moiety of GA into a single molecule (75, 85) . Radamide exhibited low micromolar inhibition of HSP90 as measured by Her2 degradation in MCF-7 breast cancer cells (85) . Chimeric compounds composed of radicicol's resorcinol ring and GA's quinone ring produce potent HSP90 inhibitors and further derivates are likely to afford analogues with increased activity and perhaps useful alternatives to the geldanamycin derivatives in clinical trials (86, 87) .
Novobiocin. Novobiocin is a type of coumarin antibiotic isolated from streptomyces spheroids, which binds to the ATPbinding pocket of DNA gyrase thus eliciting antimicrobial activity via inhibition of ATP hydrolysis (88) (89) (90) (91) . Some studies indicated that the HSP90 N-terminal binding domain of GA and radicicol share homology to the bacterial DNA gyrase B protein adenosine triphosphate (ATP)-binding domain of novobiocin (21, 23, 37, 77, 92, 93) . Researchers began paying attention to the interaction of novobiocin and HSP90. Subsequently, Neckers et al reported that novobiocin binds to a site on HSP90 which is different from the GA/radicicol binding site and shows antitumor activity by reducing HSP90 client protein expression levels, such as p185erbB2, mutated p53, and Raf-1 in a dose-dependent fashion. They further proposed that the novobiocin binding domain is in the carboxy-terminal portion of HSP90 by using HSP90 deletion mutants (94) . Ratajczak et al proposed that novobiocin antagonizes HSP90 function by inducing a conformation favoring separation of the C-terminal domains and release of substrate (95) . However, the inhibitory effect was very poor within 500-800 μM in SKBR3 breast cancer cells (94) . Thereafter, analogues of novobiocin with more potent inhibitory activity were developed.
In 2005, Blagg et al prepared a library of novobiocin analogues, which included shortening of the amide side chain and removal of the 4-hydroxy substituent, removal of both the 4-hydroxy and amide linker, steric replacements of both the 4-hydroxy and benzamide ring, and 1,2-positional isomers of the noviosyl linkage. Among them, A4, which contains an N-acetyl side chain in lieu of the benzamide, lacks the 4-hydroxyl of the coumarin moiety, and has an unmodified diol, had a dramatic effect on the concentrations of the mutant androgen receptor, AKT, and Hif-1R at a concentration of around 1 μM in the LNCaP cell line and drastically reduced levels of the androgen receptor at lower concentrations in a wild-type androgen receptor prostate cancer cell line (LAPC-4). A4 was identified to be a potent inhibitor of the HSP90 protein-folding process (96) . They further explored the structure-activity relationships (SAR) for novobiocin and HSP90 and determined what modifications are necessary to convert a well-established, clinically used DNA gyrase inhibitor, novobiocin, into a selective inhibitor of HSP90. The 4-hydroxyl and the 3-carbamate were found to be detrimental for HSP90 inhibitory activity, but are critical for DNA gyrase inhibitory activity. According the SAR, they prepared the natural product derivatives, DHN1 and DHN2, which were selective for HSP90 and not DNA gyrase (97) . The set-up of structure activity relationships for novobiocin and HSP90 are essential for exploring new coumermycin analogues with better inhibitory activity and less toxicity.
In 2006, Blagg et al developed dimeric variants of A4 exhibiting more inhibitory effective of dimeric natural product against Hsp90 protein folding machinery (98, 99) . A series of A4 analogues were prepared via linking A4 dimers by metaand para-phthalic acid and utilizing the cross-metathesis of olefins to generate a series of compounds that contained various methylene spacers in the tether (99) . They found the more flexible derivative 33 dimers containing the olefinic linkers proved to be most active, which caused the degradation of HSP90-dependent substrates in a concentration-dependent manner without additional affect to the non-HSP90-dependent proteins. Further, they proposed that the geometry of the olefin responsible for dimerization is critical for inhibitory activity (99) . Considering the structure-activity relationships (SAR), many other monomeric compound based on the A4 scaffold and the natural product novobiocin were developed (100). Two small molecule libraries were prepared and evaluated for anti-proliferative activity against several cancer cell lines. The first library explored optimization of benzamide containing a p-methoxy and a m-phenyl substituent and the second focused on the incorporation of heterocycles into the benzamide region in order to investigate hydrogen bond donor/acceptor interactions. Especially, 2-indoleamide-46 was identified as the most potent inhibitor which inhibited cancer cell growth via inducing degradation of HSP90-dependent client proteins including Her2, Raf and Akt in a concentration-dependent manner (100) .
In 2007, a parallel library of noviosylated coumarin analogues was envisioned according to the SAR, which aimed at HSP90 inhibition. Fifty-six noviosylated coumarin analogues were synthesized, omitting 4-hydroxyl and 3-carbamate and providing additional hydrophobic and hydrogen bonding interactions by the incorporation of additional functionalities. Biological studies with these compounds are currently under investigation and the results from such studies will promote the development of optimized derivatives of coumarin with better inhibitory effects for HSP90 (101) .
Another research group developed novel novobiocin analogues which lack the noviose moiety including those that connect the substituted coumarin ring to the aryl moiety through amide, retroamide, and alkyne linkage. The analogues labeled 6e and 6f were found to be more potent than novobiocin in the biological assay, such as by inhibiting of E2-induced and basal transactivation capacity of ERR, inducing a proteasome-mediated degradation of ERR, HER2, Raf-1 and cdk4, inhibiting the cell cycle, and promoting apoptosis and improving growth inhibition potential (102) . Subsequently, they prepared the denoviose analogues bearing a tosyl group on the 4-position, with the removal of C7/C8 substituents, which exhibited increased inhibitory activity against the HSP90 protein folding process (103) .
(-)-EGCG.
Green tea is one of the most widely consumed beverages in the world. The (-)-epigallocatechin-3-gallate [(-)-EGCG] is an abundant catechin in green tea and a potent chemoprevention and anticancer component (104) . (-)-EGCG was reported to inhibit the transcriptional activity of the aryl hydrocarbon receptor (AhR) via direct binding to the Cterminal region of HSP90 (105) . Recent studies have indicated that the binding of (-)-EGCG to HSP90 affects the association of HSP90 with its co-chaperones including Akt, Cdk4, Raf-1, Her-2 and pERK, thus inducing degradation of these client proteins, resulting in anti-proliferating effects in pancreatic cancer cells (106) .
Gedunin and celastrol.
Gedunin is a tetranortriterpenoid isolated from the Indian neem tree, which exhibits antimalarial, insecticidal and anticancer activity (107) (108) (109) . Celastrol (tripterine) is a triterpenoid from the celastracae family and is extracted from Tripterygium wilfordii Hook F, and has shown anti-inflammatory and anti-proliferation effects in various cancer cells such as leukemia, gliomas and prostate (110) (111) (112) (113) . Gedunin and celastrol were identified to be HSP90 inhibitors via a connectivity map, a gene expression-based strategy (114, 115) . Gedunin and celastrol decrease the levels of a range of HSP90 client proteins and inhibit HSP90 activity itself in a cellular context directly or indirectly. Notably, gedunin and celastrol were found to inhibit HSP90 function by a different mechanism than existing N-terminal HSP90 inhibitors, thus they might act synergistically with existing modes of HSP90 ATP-binding site inhibition to inhibit HSP90 client signaling and viability in a cellular context (115) . Subsequent studies reported that celastrol disrupted the proteinprotein interaction of HSP90-Cdc3, resulting in the induction of HSP90 client protein degradation, which provides a novel mechanism for HSP90 inhibition against pancreatic cancer cells (116). Recently Sreeramulu et al proposed that celastrol inactivates Cdc37 by covalently binding to it or by forming either an intra-or intermolecular protein disulfide and the binding of celastrol induces large changes in conformation of the N-terminal kinase-binding domain and also the middle HSP90N-binding domain of Cdc37, thereby disrupting the Cdc37-Hsp90N complex which is crucial for stabilizing oncogenic kinases in various cancers (117) .
Derrubone. The natural product derrubone was found to be a new HSP90 inhibitor by screening a large library of known ONCOLOGY REPORTS 23: 1483 -1492 drugs, experimental bioactives and pure natural products (118) . Derrubone inhibits HSP90-dependent refolding of luciferase, exhibits potent anti-proliferation and Her2 degradation in human breast cancer cell lines and down-regulates numerous HSP90 client proteins in a concentration-dependent manner (118) . Subsequent biological evaluation of derrubone and its analogues identified several compounds which exhibit low micromolar inhibitory activity against breast and colon cancer cell lines (119) .
Purine scaffold HSP90 inhibitors. Due to the disadvantages of established inhibitors, the identification of new HSP90 inhibitors with improved structural characteristics and better pharmacological profiles became a priority in the field. Thus purine scaffold HSP90 inhibitors were developed.
In 2001, Chiosis et al designed a novel compound that interacts with the HSP90-nucleotide binding pocket by using the structure of the co-crystals of HSP90 and its ligands (GA, RD and adenine nucleotides). The designed compound PU3 competes with GA to bind to HSP90A with a relative affinity of 15-20 μM. PU3 causes the degradation of HER kinases, estrogen receptor and Raf kinase, and growth inhibition and differentiation of human cancer cells, whose effects were similar to those induced by GA and RD (120) . Also, PU3 is soluble, easily synthesized, and may be less toxic and adaptable to oral administration. Although PU3 is less potent, it is a first generation lead compound and the structural skeleton of PU3 allows for extensive chemical modifications in the pursuit of derivatives with increased binding affinity, activity, solubility and therapeutic effects (120) . Just as expected, the same research group developed a small library of derivatives of PU3 that resulted in a compound with 30-times better cellular effects than PU3 and display a relative binding affinity for HSP90 of 0.55 μM which is similar to 17-AAG. Especially compound 71 caused growth arrest and degradation of the oncogenic Her2 tyrosine kinase at low micromolar (IC50=2 mM) concentrations. Compound 71 is also water soluble at the tested concentrations and is amenable for oral administration (121) . Another compound of this library, PU24FCL exhibits antitumor activities in both in vitro and in vivo models of cancer (122) . Subsequently, several 8-arylsulfanyl, -sulfoxyl and -sulfonyl adenine derivatives of the PU-class were synthesized and retain the activity of the methylene linker compounds (X3=CH2) and are also chemically flexible which allows for extensive SAR studies (123) . Recently, two research groups disclosed the 8-(phenylsulfanyl) purine series with ionizable groups appended at the end of the N(9) substituents, which showed improved oral bioavailability and measurable antitumor activity (124, 125) .
BIIB021(CNF2024) is the first synthetic HSP90 inhibitor to enter Phase I clinical trials, and was developed based on purine-scaffolds (126) . BIIB021 has shown potent antitumor activity both in vivo and in vitro research of many kinds of tumors (127) (128) (129) . BIIB021 is currently undergoing phase I/II clinical trials and exhibits superior pharmaceutical properties and bioavailability (130) .
Pyrazole scaffold inhibitors. The diaryl pyrazole resorcinols were identified by high throughput screening as a new class of HSP90 inhibitors (131-133) . The novel synthetic 3,4-diaryl pyrazole resorcinol inhibitor, CCT018159, was identified and showed potent antitumor activity in vitro (132, 134) . The structure-based design of CCT018159 generated a series of active pyrazole scaffold analogues, that display inhibition of cell proliferation similar to clinically evaluated 17-AAG. The crystal structure of the most potent new compound (VER-49009) bound to the target enzyme was determined and confirmed by experiment. VER-49009 binds to the ATP binding site of HSP90 with an IC50 of 25 nM in a fluorescence polarization (FP) assay and has anti-proliferative activity against HCT116 colon cancer cells, with a GI50 of 260 nM (135) .
Subsequent structure-based design generated the significantly improved isoxazole resorcinol NVP-AUY922, which is currently under phase I/II clinical trials in cancer patients (136) . NVP-AUY922 has excellent potency against HSP90 in an FP binding assay (IC50=21 nM), inhibits proliferation in a wide range of human cancer cell lines with an average GI50 of 9 nM and shows excellent efficacy in a range of subcutaneous and orthotopic human tumor xenograft models covering major cancer types and diverse oncogenic profiles. In addition, it is retained in HCT116 xenograft tumors at concentrations well above the GI50, with a half-life of 9.5 h following i.p. administration at 50 mg/kg qd (136) . During its early clinical phases, it was considered that PET biomarkers could aid in the optimization of dosing and dose schedule (137) .
SNX-2112
. SNX-2112 is a newly developed HSP90 inhibitor that is unrelated to any previously known scaffold. The SNX-2112 scaffold was identified by screening the purinebinding proteome for non-quinone and non-purine-containing scaffolds that bind selectively to HSP90 and it is panselective for the HSP90 family in that it binds to Hsp90a, HSP90B, Grp94 and Trap-1. A water-soluble prodrugs of SNX-2112, SNX-5542, was developed and showed improved solubility and pharmacologic properties due to the variable oral bioavailability of SNX-2112 (138) . SNX-2112 and its prodrug SNX-5542 showed similar activity as 17-AAG, such as the degradation of HER2, mutant epidermal growth factor receptor and other client proteins; the inhibition of extracellular signal regulated kinase and Akt activation, and the induction of an Rb-dependent G1 arrest with subsequent apoptosis (138) . Further study exhibited that SNX-2112 is highly potent against hematologic tumor cells via abrogating signaling which is dependent on Akt and Erk and induces tumor growth inhibition and prolongs survival in a murine xenograft model of human multiple myeloma (139, 140) . SNX-2112 is now in multiple phase I clinical trials.
STA9090. STA9090 developed by Synta Pharmaceuticals
Corp. is a novel resorcinol containing a triazole compound unrelated to geldanamycin and acts as a potent HSP90 inhibitor (141) . STA-9090 causes the degradation of multiple HSP90 client proteins, the killing of a wide variety of human cancer cell lines at low nano molar concentrations in vitro, and has shown potent anticancer activity in human xenograft tumor models (142) . STA9090 is currently undergoing phase I or phase I/II trials (http://www.gistsupport.org/treatments/ emerging-treatments/HSP90-inhibitors/sta-9090.php).
Conclusions
The HSP90 molecular chaperone family is highly conserved and expressed in various organisms ranging from prokaryotes to eukaryotes. HSP90 proteins play essential housekeeping functions and play an important role in the progression of malignant disease. HSP90 proteins are ATP-dependent chaperones and the binding and hydrolysis of ATP is coupled to conformation changes of HSP90, which facilitates client protein folding and maturation. Many natural and synthetic molecular compounds have been proposed as promising cancer therapies via disrupting the formation of complex ATP-HSP90-client proteins.
